An Open Label, Randomized, Parallel Controlled, Multicenter Phase IIa Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Flonoltinib Maleate Tablets in the Treatment of Hydroxyurea or Interferon Resistant/Intolerant Polycythemia Vera
Latest Information Update: 10 Mar 2026
At a glance
- Drugs Flonoltinib maleate (Primary)
- Indications Myelofibrosis; Myeloproliferative disorders; Polycythaemia vera; Thrombocytopenia; Thrombocytosis
- Focus Therapeutic Use
- Sponsors Chengdu Zenitar Biomedical Technology
Most Recent Events
- 04 Mar 2026 Status changed from active, no longer recruiting to recruiting.
- 26 Nov 2025 New trial record